Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 05, 2026
Why Is Regal Rexnord Corporation (RRX) Stock Down -12.62% Today?

Why Is Regal Rexnord Corporation (RRX) Stock Down -12.62% Today?

Key Takeaways

  • Regal Rexnord shares plunged 12.62% to $192.28 in Wednesday's session, following the release of second-quarter 2026 earnings that disappointed on revenue and raised margin concerns.
  • Revenue missed Wall Street estimates: Q2 revenue of $1.56 billion fell short of the $1.58 billion consensus, despite rising 4.2% year over year.
  • Organic growth fell short of expectations at 3.3%, while the Power Efficiency Solutions segment contracted 5.5% amid weakness in residential HVAC and pool markets.
  • The selloff stood in stark contrast to the broader market, with the S&P 500 and Dow hitting fresh record highs on strong AI-linked earnings and easing geopolitical tensions.
  • Traders are now watching whether daily order momentum — up 8.8% year over year — can translate into better second-half execution and whether the stock's elevated valuation can be defended.

Opening Summary

RRX, the Milwaukee-based industrial manufacturer formally known as Regal Rexnord Corporation, saw its shares tumble 12.62% on Wednesday, closing the session near $192.28 after posting a prior close of $220.04. The company, which designs and manufactures electric motors, power transmission components, automation subsystems, and air-moving products for industrial end markets worldwide, reported second-quarter 2026 results before the opening bell. While adjusted earnings per share of $2.99 handily beat the analyst consensus of $2.58, a revenue shortfall and cautious commentary around margins and productivity triggered a sharp selloff that erased months of gains in a single session.

Earnings Results: Revenue Miss Overshadows Profit Beat

Regal Rexnord delivered a classic "beat on earnings, miss on revenue" quarter that markets rarely reward. Q2 revenue came in at $1.56 billion, representing 4.2% year-over-year growth but falling roughly $20 million short of Wall Street's $1.58 billion estimate. Organic revenue growth of 3.3% similarly undershot projections. The earnings beat — adjusted EPS of $2.99 versus the $2.58 consensus — and adjusted EBITDA of $366.6 million that comfortably exceeded the $340 million estimate were ultimately overshadowed by investors' laser focus on the top-line shortfall.

Segment Divergence: Automation Strength, Efficiency Weakness

The quarter revealed a stark divergence across Regal Rexnord's three operating segments. The Automation & Motion Control (AMC) division shone brightest, with net sales surging 16.2% to $477.7 million, driven by robust demand in data center, discrete automation, and aerospace & defense end markets. Industrial Powertrain Solutions (IPS) posted a more modest 3.0% increase to $669.4 million, with strength concentrated in the energy market. However, Power Efficiency Solutions (PES) proved to be a significant drag, with sales declining 5.5% to $411.3 million as residential HVAC and pool markets remained soft. The uneven segment performance reinforced concerns about the company's exposure to cyclical consumer-facing end markets even as its industrial automation tailwinds accelerate.

Guidance and Margin Concerns Weigh on Sentiment

Management narrowed its full-year 2026 adjusted EPS guidance to a range of $10.35 to $10.85, maintaining a $10.60 midpoint that sits fractionally below the analyst consensus of $10.64. CFO Rob Rehard flagged "a longer timeframe to realize planned productivity gains" and "a delay in price realization relative to a faster pace of inflation," comments that spooked a market already nervous about margin trajectories across the industrial sector. The guidance also incorporates $0.57 per share in benefits from IEEPA tariff refunds, a non-recurring tailwind that some analysts stripped out when assessing the underlying earnings power. The company's net debt to adjusted EBITDA ratio ended the quarter at 3.06x, with management targeting a decline below 3.0x in the second half of 2026.

Market Context and Trading Activity

The severity of RRX's decline was particularly notable given the overwhelmingly positive tone across equity markets on Wednesday. The S&P 500 and Dow Jones Industrial Average both closed at record highs, powered by blowout AI-linked earnings from the likes of PLTR and CAT, while falling oil prices on hopes of a U.S.-Iran diplomatic breakthrough further boosted risk appetite. The industrials sector broadly participated in the rally, making RRX's double-digit percentage drop a clear company-specific event rather than a sector-driven move. Volume was significantly elevated, with the stock trading multiples of its average daily turnover as institutional investors recalibrated positions following the earnings release. From a technical perspective, the selloff pushed shares decisively below key moving averages and erased the stock's gains from the past several weeks.

What Comes Next for RRX

The path forward for Regal Rexnord hinges on whether the positive order momentum — enterprise daily orders up 8.8% year over year, with AMC daily orders jumping 17.1% — translates into accelerating revenue growth in the back half of 2026. The data center buildout, aerospace and defense spending, and energy market strength provide genuine secular tailwinds. However, persistent weakness in residential HVAC and pool markets, coupled with the margin headwinds highlighted by management, present tangible risks. Investors will closely scrutinize the company's progress on debt reduction, with the sub-3.0x leverage target serving as a key milestone. The appointment of new CEO Aamir Paul adds an additional layer of uncertainty as the market assesses any potential strategic shifts under fresh leadership. With the stock having rallied roughly 47% year-to-date prior to Wednesday's plunge, the valuation compression that followed the earnings miss suggests the bar for a recovery remains high.

Trending AI Robots

For traders seeking systematic, data-driven approaches to navigating volatile earnings seasons, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to shifting market conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this dedicated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore diverse approaches to automated trading. Visit the Trending AI Robots page to discover which strategies are currently delivering standout results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RRX

RRX in upward trend: price rose above 50-day moving average on August 04, 2026

RRX moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RRX's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on RRX as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RRX just turned positive on August 04, 2026. Looking at past instances where RRX's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RRX advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .

RRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for RRX crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RRX entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.152) is normal, around the industry mean (6.305). P/E Ratio (51.172) is within average values for comparable stocks, (62.943). Projected Growth (PEG Ratio) (2.058) is also within normal values, averaging (2.112). Dividend Yield (0.006) settles around the average of (0.018) among similar stocks. P/S Ratio (2.447) is also within normal values, averaging (141.004).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Illinois Tool Works (NYSE:ITW), Ingersoll Rand (NYSE:IR), Generac Holdings (NYSE:GNRC).

Industry description

The industry makes and maintains machines for consumers, the industry, and most other companies. While it has traditionally been categorized as heavy industry, some smaller companies are also branching into the light category. The industry is pivotal in providing the equipment for production in businesses like agriculture, mining, industry and construction, gas, electricity and water utilities. It also supplies supporting equipment for almost all sectors of the economy, such as equipment for heating, and air conditioning of buildings. Illinois Tool Works Inc., Parker-Hannifin Corporation and Rockwell Automation Inc are some of the major U.S. companies operating in this industry.

Market Cap

The average market capitalization across the Industrial Machinery Industry is 17.26B. The market cap for tickers in the group ranges from 1.55K to 271.27B. GEV holds the highest valuation in this group at 271.27B. The lowest valued company is XEBEF at 1.55K.

High and low price notable news

The average weekly price growth across all stocks in the Industrial Machinery Industry was 8%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 2%. BWEN experienced the highest price growth at 26%, while LBGJ experienced the biggest fall at -100%.

Volume

The average weekly volume growth across all stocks in the Industrial Machinery Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was -95% and the average quarterly volume growth was -29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 55
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 72
Seasonality Score: -34 (-100 ... +100)
View a ticker or compare two or three
RRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of electrical and mechanical motion control products

Industry IndustrialMachinery

Profile
Details
Industry
Industrial Machinery
Address
111 West Michigan Street
Phone
+1 608 364-8800
Employees
32100
Web
https://www.regalrexnord.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.